Rondo Therapeutics Closes $67 Million Series A Financing to Advance Next Generation Immuno-Oncology Platform for Solid Tumors
Rondo Therapeutics, a biopharmaceutical company advancing a next-generation immuno-oncology platform for treating solid tumors, today announced the closing of an oversubscribed $67 million Series A financing.
Rondo Therapeutics Rounds Up $67 Million for Cancer Treatments
Venture capitalists have invested $67 million in Rondo Therapeutics Inc., a cancer drug developer led by entrepreneurs who previously helped start successful biotechnology company Teneobio Inc.
A dynamic oncology duo team up on an I/O startup focused on next-gen solid tumor fighters
In the notoriously flighty biotech industry, longtime partnerships aren’t necessarily the norm. But a pair of oncology vets with a history of collaboration apparently likes working together just fine — and now they’re kickstarting an upstart firm on the hunt against solid tumors.